Foreign Exchange Rates Said To Bode Well For Chinese Pharmas
This article was originally published in PharmAsia News
Chinese drug makers can expect to benefit by a foreign exchange rate that makes the yuan stronger against the American dollar and other currencies. The situation is expected to lead to greater foreign investments in China's industry and give drug makers greater domestic purchasing power. At the same time, foreign competitors face greater operating costs in China, leading them to expect a greater contribution from alliances with other Chinese firms. The estimates come from Synthetic Organic Chemical Manufacturers Association, a global group for chemical companies. (Click here for more
You may also be interested in...
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.
US regulators refused to accept the file for one of Y-mAbs's neuroblasoma drugs – omburtamab – in October but have given the green light to a second one, naxitamab.